Antiarrhythmic Treatment in Heart Failure
Hilke Könemann1, Sati Güler-Eren2, Christian Ellermann2
1Department of Cardiology II: Electrophysiology, University Hospital Münster, Münster, Germany. hilke.koenemann@ukmuenster.de.
Current Heart Failure Reports
|January 15, 2024
Summary
Arrhythmias in heart failure (HF) increase mortality risk. Early rhythm control, catheter ablation, and ICD therapy are key, while drug therapy is adjunctive, requiring a multimodal approach for optimal patient outcomes.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Arrhythmias are prevalent in heart failure (HF) patients, significantly increasing mortality and morbidity risks.
- Effective antiarrhythmic strategies are crucial for managing patients with heart failure.
Purpose of the Study:
- To review current therapeutic approaches for managing arrhythmias in patients with heart failure.
- To highlight recent advancements and evidence-based strategies in antiarrhythmic treatment for HF.
Main Methods:
- Review of current clinical guidelines and recent clinical trial data.
- Analysis of pharmacological, device-based (ICD), and interventional (catheter ablation) therapies.
- Integration of guideline-directed medical therapy for HF with antiarrhythmic interventions.
Main Results:
- Early rhythm control and catheter ablation show prognostic benefits, particularly in HF with reduced ejection fraction.
- Implantable cardioverter-defibrillator (ICD) therapy is essential for preventing sudden cardiac death, though risk stratification remains challenging.
- Antiarrhythmic drug therapy serves an adjunctive role for symptomatic relief without prognostic benefit and carries proarrhythmic risks.
Conclusions:
- Antiarrhythmic therapy in HF necessitates a systematic, multimodal strategy.
- Integrating pharmacological, device, and interventional treatments alongside HF guideline-directed medical therapy is essential.
- Optimizing antiarrhythmic management improves outcomes for patients with heart failure and arrhythmias.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
01:28Disturbances in Heart Rhythm
961
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
961
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
746
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
746
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432